Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals

- KRYSTEXXA® (pegloticase), the only product approved for refractory chronic gout, included in the sale.

Dec 11, 2013, 07:00 ET from Savient Pharmaceuticals, Inc. from ,Crealta Pharmaceuticals

$countyNameToPathMap.put("sp